viral
infect
ebola
sever
acut
respiratori
syndromemiddl
east
respiratori
syndrom
west
nile
viru
emerg
seriou
health
threat
effect
therapi
infect
littl
commerci
potenti
high
prioriti
pharmaceut
industri
howev
academ
commun
activ
area
mani
year
challeng
take
academ
virolog
knowledg
drug
discoveri
develop
domain
one
approach
use
consortia
publicpriv
partnership
articl
highlight
ongo
effort
usa
public
fund
govern
sourc
support
research
effort
appear
commerci
valu
key
success
find
way
combin
differ
cultur
oper
valu
reward
system
product
collabor
identifi
new
antivir
past
year
wit
emerg
reemerg
human
viral
infect
caus
signific
morbid
mortal
includ
sar
mer
coronavirus
highli
pathogen
influenza
pandem
influenza
monkeypox
west
nile
viru
wnv
chikungunya
viru
dengu
fever
viru
arguabl
efficaci
therapi
exist
diseas
develop
resist
exist
drug
remain
constant
concern
signific
effort
gone
identifi
develop
vaccin
therapeut
agent
one
infect
thu
far
success
limit
perhap
one
alarm
certainli
one
devast
recent
exampl
reemerg
infecti
diseas
outbreak
ebola
zair
west
africa
largest
record
histori
although
prior
outbreak
ebola
zair
occur
remot
area
central
africa
epidem
began
west
african
nation
guinea
believ
epidem
start
singl
introduct
viru
human
popul
decemb
boy
die
present
fever
vomit
black
stool
outbreak
subsequ
spread
humantohuman
transmiss
highli
popul
area
liberia
sierra
leon
nigeria
seneg
mali
octob
approxim
probabl
suspect
laboratori
confirm
case
ebola
report
death
case
includ
healthcar
worker
infect
estim
die
outbreak
carri
usa
europ
via
resid
healthcar
worker
expos
viru
west
africa
six
case
two
import
case
includ
one
end
death
two
acquir
case
healthcar
worker
occur
usa
outbreak
clearli
illustr
limit
abil
current
public
health
medic
research
develop
system
respond
rapid
emerg
rare
highli
virul
infecti
diseas
particularli
dens
popul
urban
center
although
attempt
made
util
vaccin
therapeut
agent
develop
mani
primari
indic
differ
viru
comprehens
report
effect
intervent
may
appear
date
cite
addit
exampl
decad
ago
total
number
case
sar
novemb
august
alon
mortal
major
case
occur
southeast
asia
canada
recent
novel
coronaviru
identifi
middl
east
caus
respiratori
ill
dub
middl
east
respiratori
syndrom
coronaviru
merscov
viru
genet
phenotyp
distinct
coronaviru
caus
sar
epidem
howev
like
peopl
infect
sar
viru
peopl
infect
merscov
quickli
develop
sever
respiratori
ill
approxim
four
everi
ten
patient
diagnos
mer
die
exist
therapi
patient
sar
mer
includ
ribavirin
corticosteroid
interferon
effect
clearli
need
develop
therapeut
biolog
threat
anoth
emerg
infect
pandem
potenti
highli
pathogen
influenza
sinc
case
report
mortal
rate
approach
treatment
neuraminidas
inhibitor
shown
benefit
howev
emerg
resist
occur
recent
engin
highli
pathogen
gener
virus
readili
transmiss
ferret
result
signific
debat
among
scientist
ethicist
foundat
research
inadvert
intent
releas
engin
virus
gener
popul
could
devast
consequ
case
either
sar
influenza
detect
usa
probabl
import
diseas
widespread
global
travel
unreason
usa
continu
experi
multipl
emerg
infect
exampl
introduct
wnv
caus
clinic
infect
rang
sever
total
asymptomat
uncompl
wnv
fever
fatal
meningoenceph
decemb
case
report
cdc
usa
death
resurg
wnv
diseas
case
death
report
cdc
fluctuat
number
report
case
document
diseas
occur
annual
usa
therapi
includ
administr
high
titer
wnv
immun
globulin
whitley
et
al
person
experi
proven
efficaci
furthermor
small
molecul
drug
develop
second
monkeypox
member
orthopox
viru
famili
inadvert
import
usa
shipment
giant
gambian
rat
exot
pet
trade
quarantin
anim
transmit
viru
pet
prairi
dog
highli
suscept
infect
may
monkeypox
spread
approxim
individu
contact
anim
result
clinic
case
diseas
one
life
threaten
still
us
fdaapprov
drug
treatment
poxviru
infect
third
usa
experienc
pandem
influenza
caus
morbid
mortal
select
popul
particularli
young
adult
pregnant
women
mortal
great
associ
pandem
need
improv
antivir
therapi
becam
appar
especi
drugresist
strain
circul
global
fourth
decad
ago
chikungunya
rare
detect
usa
even
global
travel
return
area
diseas
endem
howev
case
began
identifi
first
travel
return
asia
africa
area
near
indian
ocean
subsequ
start
travel
return
caribbean
local
transmiss
florida
puerto
rico
us
virgin
island
began
identifi
start
year
diseas
nation
notifi
condit
report
cdc
fifth
dengu
report
puerto
rico
also
continent
usa
lastli
although
preval
usa
yet
recent
outbreak
emerg
infect
zika
viru
brazil
result
microcephali
babi
born
infect
mother
caus
concern
monitor
emerg
infecti
diseas
includ
cite
appear
highprior
target
pharmaceut
industri
attribut
multipl
factor
includ
occurr
diseas
mostli
poor
develop
countri
incid
diseas
low
sporad
make
difficult
conduct
clinic
trial
meet
us
fda
standard
market
size
drug
uncertain
make
difficult
recoup
direct
develop
cost
therefor
industri
focus
effort
drug
chronic
diseas
use
regularli
consequ
substanti
greater
commerci
potenti
gener
outsourc
basic
discoveri
pharma
opportun
save
initi
research
cost
confid
pursu
classic
develop
oppos
research
nonetheless
advantag
pharma
develop
drug
emerg
infect
abil
appli
secur
us
fda
voucher
appli
expedit
review
tradit
medic
howev
smaller
biotechnolog
compani
still
difficult
obtain
earli
stage
financ
focu
discov
develop
drug
emerg
reemerg
infect
margin
commerci
potenti
given
profound
threat
diseas
pose
fortun
mani
academ
drug
discoveri
center
start
within
last
decad
actual
focu
infecti
diseas
perhap
due
desir
meet
unmet
medic
need
need
differenti
academ
effort
commerci
one
thu
direct
competit
entiti
significantli
greater
financi
resourc
discuss
depth
academ
drug
discoveri
effort
benefit
depth
knowledg
biolog
medicin
often
lack
infrastructur
expertis
beyond
target
identif
hit
identif
initi
hit
lead
effort
contrast
strength
commerci
enterpris
resid
target
valid
appli
medicin
chemistri
preclin
toxicolog
clinic
trial
design
execut
well
project
manag
infrastructur
necessari
navig
novel
chemic
seri
concept
investig
new
drug
ind
ultim
new
drug
applic
nda
establish
product
collabor
academia
industri
recruit
strength
parti
focus
effort
sourc
fund
must
identifi
could
includ
govern
sourc
biomed
advanc
research
develop
author
whose
mission
advanc
develop
procur
medic
countermeasur
pandem
influenza
emerg
infecti
diseas
addit
sourc
includ
advanc
develop
arm
depart
defens
biodefenserel
agent
medic
countermeasur
system
parent
entiti
joint
program
execut
offic
nih
cdc
well
privat
sourc
gate
foundat
wellcom
trust
earli
govern
fund
use
establish
program
advanc
proofofconcept
stage
facilit
secur
privat
fund
commerci
develop
adequ
fund
academ
industri
consortia
well
equip
address
unmet
medic
need
acceler
develop
medic
countermeasur
infect
tremend
growth
recent
year
number
academ
drug
discoveri
center
prompt
part
extern
research
develop
r
pharmaceut
compani
enhanc
focu
nih
translat
research
research
specif
focus
develop
relev
innov
need
product
exampl
format
nation
center
advanc
translat
scienc
associ
center
translat
scienc
award
direct
toward
effort
mani
academ
drug
discoveri
center
incorpor
expert
pharmaceut
industri
leadership
posit
addit
collabor
network
form
academ
drug
discoveri
consortium
addc
facilit
commun
coordin
center
addc
facilit
match
interest
compani
specif
target
andor
diseas
appropri
academ
partner
websit
list
center
program
event
job
post
partnership
opportun
contribut
activ
member
might
expect
mani
academ
enterpris
focu
earlystag
project
survey
frye
et
al
show
mani
project
earli
stage
name
hit
lead
identif
project
clinic
develop
ind
reason
may
includ
practic
one
lower
cost
resourc
need
earlier
stage
discoveri
howev
may
strateg
well
academ
drug
discoveri
flexibl
focus
longterm
highrisk
project
sinc
immedi
sharehold
payout
expect
would
case
publicli
trade
pharmaceut
firm
note
major
fund
academ
drug
discoveri
center
tend
come
public
sourc
outcom
less
rigor
tie
develop
deadlin
gener
depend
commerci
expect
also
illustr
aforement
focu
noncommerci
orphan
diseas
ailment
afflict
develop
countri
say
desir
licens
revenu
exist
financi
success
emori
northwestern
univers
minnesota
princeton
undoubtedli
contribut
highlevel
support
novel
drug
discoveri
program
variou
institut
howev
except
academ
enterpris
typic
lack
infrastructur
expertis
later
stage
effort
move
lead
clinic
candid
frye
overview
academ
drug
discoveri
usa
note
approxim
half
center
perform
vivo
proofofconcept
test
even
basic
distribut
metabol
pharmacokinet
evalu
dmpk
center
capabl
later
stage
project
public
fund
nih
complement
resourc
kind
andor
milestonebas
licens
incom
industri
partner
appropri
intellectu
properti
ip
protect
new
composit
matter
mani
academ
institut
address
ip
matter
inappropri
focu
patent
target
assay
invari
difficult
protect
less
valu
addit
case
patent
file
earli
invent
fulli
vet
anoth
misconcept
patent
file
investig
free
disclos
invent
protect
care
consider
must
given
applic
publish
versu
work
actual
publish
peer
review
journal
disclos
public
forum
case
would
requir
delay
public
howev
one
main
problem
one
work
univers
environ
academ
promot
tenur
system
reward
faculti
public
extramur
grant
philosophi
tend
incompat
timelin
associ
drug
discoveri
develop
order
obtain
protect
chemic
seri
public
delay
patent
actual
publish
typic
month
file
sever
academ
group
circumv
publish
versu
patent
issu
chemic
matter
delay
public
lead
seri
publish
compound
seri
less
interest
cours
question
remain
whether
univers
research
teach
mission
compat
delay
public
establish
accept
ip
posit
academ
institut
overcom
sourc
friction
creat
two
parallel
track
one
academ
staf
traine
focus
basic
scienc
highqual
data
develop
tool
compound
public
one
commerci
staf
research
industri
experi
focu
gener
compound
ip
academ
track
would
follow
usual
promot
tenur
guidelin
commerci
one
mimick
promot
system
seen
pharmaceut
biotechnolog
compani
integr
would
mediat
senior
manag
would
also
decid
track
appropri
particular
project
individu
merit
drug
discoveri
academ
set
consensu
use
rigor
project
manag
applic
qualiti
control
qualiti
assur
principl
util
industri
would
benefici
exampl
latter
hit
identifi
highthroughput
screen
filter
elimin
compound
reactiv
group
standard
practic
commerci
screen
oper
often
overlook
academ
effort
similar
vein
ident
activ
hit
lead
molecul
confirm
proceed
addit
biolog
studi
final
effort
put
valid
target
academ
drug
target
clinic
evid
valid
frye
survey
partner
academ
enterpris
commerci
entiti
activ
extrem
well
thu
immedi
merit
sinc
would
avoid
duplic
wast
resourc
least
two
distinct
type
consortia
sometim
also
refer
allianc
academia
notforprofit
exampl
alabama
drug
discoveri
allianc
univers
alabama
birmingham
partner
southern
research
notforprofit
research
institut
also
locat
birmingham
al
usa
exampl
although
antimicrobi
antivir
space
includ
opportun
academ
research
collabor
nonprofit
global
allianc
tb
drug
develop
whose
partner
includ
industri
ngo
govern
foundat
provid
infrastructur
expertis
fund
similar
structur
provid
tre
canto
open
lab
foundat
provid
opportun
scientist
around
world
collabor
team
pharma
expertis
gsk
well
particip
partner
area
drug
discoveri
develop
malaria
tuberculosi
leishmaniasi
trypanosomiasi
among
other
categori
probabl
exampl
janssen
allianc
vanderbilt
univers
eisai
collabor
john
hopkin
neurosci
space
antivir
arena
prime
exampl
gilead
scienc
partnership
antivir
drug
discoveri
develop
center
niaidfund
consortium
coordin
univers
alabama
birmingham
see
box
anoth
earlier
exampl
yield
success
nihfund
southeast
region
center
excel
emerg
infect
biodefens
serceb
aid
chimerix
earli
develop
brincidofovir
potenti
prophylaxi
treatment
smallpox
notforprofit
partner
southern
research
provid
expertis
drug
discoveri
develop
particular
assay
develop
highthroughput
screen
medicin
chemistri
gilead
commerci
partner
contribut
screen
librari
provid
addit
chemistri
expertis
later
stage
drug
develop
sinc
sr
screen
librari
virus
allow
identif
broadspectrum
compound
addit
compound
activ
one
type
viru
mention
perspect
activ
manag
consortium
key
achiev
via
administr
core
hous
uab
facilit
reach
consortium
agreement
ensur
commun
partner
monthli
confer
call
annual
inperson
meet
addit
ad
hoc
discuss
administr
core
also
establish
extern
advisori
board
meet
investig
annual
inperson
meet
advis
project
portfolio
next
step
importantli
extern
advisori
board
member
rich
background
antivir
drug
discoveri
either
academia
pharmaceut
industri
abil
critic
look
compound
progress
pathway
differ
project
case
strength
partner
complement
combin
indepth
understand
biolog
academ
set
knowhow
drug
discoveri
develop
notforprofit
entiti
southern
research
tb
allianc
tre
canto
open
lab
commerci
pharmaceuticalbiotechnolog
compani
addit
two
model
describ
addit
creativ
way
capit
particular
strength
certain
institut
uniqu
particular
environ
cultur
exampl
latter
offer
drug
innov
ventur
emori
drive
llc
drive
form
wholli
own
subsidiari
emori
univers
staf
expertis
financ
direct
develop
drug
emergingreemerg
diseas
alli
common
manag
emori
institut
drug
develop
eidd
taken
togeth
drive
eidd
constitut
freestand
biotechnolog
compani
direct
access
intellectu
physic
asset
emori
univers
possess
suffici
infrastructur
advanc
candid
phase
iia
clinic
trial
util
combin
resourc
extern
collabor
outsourc
anoth
uniqu
dimens
drive
form
forprofit
spinout
rais
equiti
capit
financ
develop
promis
drug
candid
particip
academ
consortia
leverag
discoveri
develop
capac
straightforward
drive
compani
alreadi
oper
within
academ
framework
matter
type
consortium
abil
find
fund
support
sustain
consortium
activ
remain
challeng
common
sourc
includ
public
fund
provid
nih
niaid
particular
prime
exampl
mechan
aforement
fund
cooper
agreement
research
program
support
center
excel
translat
research
asset
identifi
mechan
carri
ind
phase
clinic
develop
consortium
tap
fund
avail
note
develop
antivir
therapeut
compound
broad
activ
desir
inhibit
emerg
infect
common
viral
ill
exist
develop
nation
impli
lack
specif
targetdrug
molecul
attribut
begin
emerg
appropri
safeti
profil
case
govern
fund
direct
toward
develop
compound
noncommerci
indic
leverag
support
concurr
develop
compound
indic
better
commerci
opportun
derisk
compound
demonstr
suitabl
pharmacokinet
toxic
profil
would
make
attract
develop
commerci
partner
collabor
institut
differ
cultur
valu
oper
level
mani
challeng
activ
manag
consortium
key
success
first
found
princip
behind
collabor
need
understood
level
senior
leadership
individu
work
bench
principl
associ
mission
vision
also
serv
guid
clarif
codif
goal
consortium
definit
constitut
success
tradit
academia
public
find
highimpact
journal
subsequ
success
extramur
grant
applic
would
consid
appropri
metric
product
often
time
incongru
metric
commerci
partner
would
typic
pursu
meet
drug
discoveri
develop
mileston
certain
time
frame
gener
ip
two
differ
set
goal
often
achiev
togeth
although
public
would
typic
delay
ip
posit
secur
mention
earlier
set
clear
expect
outset
project
critic
mitig
conflict
road
allow
academ
partner
go
collabor
thorough
understand
potenti
limit
ramif
delay
disclosur
one
frequent
stumbl
block
partner
negoti
ownership
aforement
ip
gener
framework
consid
ownership
follow
inventorship
futur
revenu
distribut
flexibl
distribut
certain
extent
among
consortium
partner
regardless
actual
contribut
one
particular
invent
provid
incent
particip
consortium
especi
multipl
project
within
consortium
portfolio
util
expertis
differ
subset
partner
institut
allud
one
typic
strength
commerci
partner
consortia
project
manag
capabl
put
place
monitor
enhanc
project
perform
alreadi
import
daytoday
oper
institut
take
even
promin
role
consortia
need
complet
clear
respons
partner
parti
includ
timelin
execut
respons
project
plan
ensur
commun
happen
right
individu
right
time
decis
made
inform
avail
one
exampl
highlight
best
practic
gilead
collabor
yale
oncolog
space
continu
commun
decis
make
loop
oper
contrast
tradit
quarterli
updat
ideal
would
project
manag
parti
minimum
point
contact
includ
commun
charg
author
followup
action
item
decis
made
final
utmost
import
leadership
involv
consortia
expertis
guid
success
enterpris
includ
deep
knowledg
biolog
drug
discoveri
well
requir
laterstag
drug
develop
activ
typic
former
resid
academ
partner
provid
innov
energi
project
latter
resid
commerci
partner
bring
timelin
critic
path
manag
tabl
howev
consortia
partner
understand
activ
make
eventu
transit
earli
decis
product
toward
latter
highli
advis
gener
compound
progress
pathway
delin
paramet
compound
need
meet
move
next
phase
drug
discoveri
develop
pipelin
includ
paramet
associ
antivir
efficaci
safeti
well
druglik
properti
importantli
document
need
clarifi
critic
path
decisionmak
paramet
versu
nice
know
studi
data
absolut
critic
move
compound
forward
potenti
therapeut
exampl
exact
mechan
action
molecular
level
need
determin
quickli
possibl
import
know
academ
virologist
want
truli
understand
biolog
target
howev
arguabl
critic
initi
phase
identifi
chemic
lead
seri
would
therefor
critic
path
rather
parallel
path
result
would
inform
project
much
later
develop
stage
extrem
import
success
ventur
partner
respect
expertis
trust
decis
rang
budget
decis
experiment
design
made
consortium
success
mind
although
contract
place
specifi
exact
contribut
partner
potenti
gain
decisionmak
author
conflict
resolut
substitut
trust
need
individu
involv
partnership
make
consortium
success
furthermor
drug
develop
almost
never
proce
initi
plan
consequ
consortium
must
abl
accommod
chang
throughout
lifetim
although
earli
tell
whether
consortia
success
rapidli
identifi
develop
new
therapi
emerg
reemerg
infect
logic
dictat
best
option
achiev
goal
fact
downsiz
inhous
research
develop
depart
commerci
oper
use
consortia
like
expand
therapeut
area
well
beyond
infecti
diseas
lesson
learn
recent
establish
consortia
need
care
record
appli
futur
collabor
infrastructur
help
address
dichotomi
academ
commerci
research
cultur
address
issu
metric
success
time
public
patent
applic
collabor
decis
make
project
manag
parti
get
educ
process
valu
partner
institut
inform
start
flow
quickli
individu
project
team
thu
streamlin
drug
discoveri
develop
process
individu
manag
inform
appropri
respect
trust
parti
involv
prove
pivot
team
member
consortia
crucial
ultim
success
recent
year
mani
viral
infect
emerg
reemerg
exampl
includ
ebola
sar
mer
pandem
influenza
west
nile
chikungunya
dengu
among
other
good
medic
countermeasur
infect
limit
treatment
support
care
role
drug
discoverydevelop
consortia
drug
discoveri
academia
commerci
reason
infect
highprior
target
pharmaceut
industri
academ
drug
discoveri
significantli
grown
last
decad
howev
focu
tend
earlystag
discoveri
lack
infrastructur
expertis
fund
go
beyond
hit
lead
effort
strength
commerci
enterpris
later
stage
discoveri
drug
develop
along
project
manag
principl
ensur
nice
complement
academ
effort
consortia
academ
experienc
drug
discoveri
develop
organ
thu
natur
solut
util
strength
viral
biolog
academia
drug
develop
knowhow
industri
consortia
typic
academ
partner
either
notforprofit
organ
commerci
pharmaceut
partner
fund
often
obtain
public
sector
nih
biomed
advanc
research
develop
author
government
health
agenc
around
world
success
depend
clariti
vision
goal
consortium
transpar
strong
manag
activ
parti
collabor
rapid
realtim
share
inform
leadership
drug
discoveri
develop
expertis
final
trust
parti
institut
individu
level
key
product
relationship
